Condition: Solid Tumours · Sponsor: AstraZeneca
The purpose of this modular, first trial in human study is to assess the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary efficacy of ascending dose levels (DLs) of AZD4956 monotherapy and in combination with other anti-cancer agents in participants with advanced/metastatic solid tumours with homologous recombination repair (HRR) deficiencies.
This description comes directly from the study's public registry record.
AstraZeneca Clinical Study Information Center · 1-877-240-9479 · information.center@astrazeneca.com
Always discuss trial participation with your own doctor first.
| Research Site | New York, New York, United States | Not Yet Recruiting |
| Research Site | Providence, Rhode Island, United States | Not Yet Recruiting |
| Research Site | Houston, Texas, United States | Not Yet Recruiting |
| Research Site | Fairfax, Virginia, United States | Recruiting |
| Research Site | Melbourne, Australia | Not Yet Recruiting |
| Research Site | Westmead, Australia | Not Yet Recruiting |
| Research Site | Chūōku, Japan | Not Yet Recruiting |
| Research Site | Kashiwa, Japan | Not Yet Recruiting |
| Research Site | Seoul, South Korea | Not Yet Recruiting |
| Research Site | Seoul, South Korea | Not Yet Recruiting |
| Research Site | Barcelona, Spain | Not Yet Recruiting |
| Research Site | Barcelona, Spain | Not Yet Recruiting |
+ 7 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07446855